"Novavax shares tumbled 16% in premarket action [14.76% down at close] after Politico reported it faces significant hurdles in proving it can manufacture a shot that meets regulators' quality standards, citing three people with direct knowledge of the company's problems. The report said Novavax's troubles mean the international consortium known as COVAX is now likely to fall short of its 2 billion dose target to lower and middle-income countries by the end of 2022 by more than 1 billion doses. The report said Novavax's difficulties are more concerning than the analytics and testing issues disclosed in Securities and Exchange Commission filings. Novavax told Politico that it still plans on filing for emergency use authorization by the end of the year and will fulfill all its committed doses both in the U.S. and globally."
https://www.marketwatch.com/story/novavax-shares-tumble-after-report-on-vaccine-manufacturing-difficulties-2021-10-20?mod=mw_latestnews